$0.17
(Market cap
$332 Mln
Recently Viewed
Clear AllMarket cap
$332 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2
Debt to Equity
0.2
Book Value
$1.2
EPS
$-0.5
Face value
--
Shares outstanding
126,564,473
CFO
$-398.71 Mln
EBITDA
$434.89 Mln
Net Profit
$433.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
| 43.1 | -26.2 | 37.4 | 305.3 | 4.6 | -24.8 | -- |
|
BSE Sensex
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
| 16.1 | -43.5 | 66.1 | -65.3 | -52.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
|
2.8 | 331.6 | 0.0 | -59.0 | -- | -32.3 | -- | 2.1 |
| 73.8 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.0 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.5 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 90.0 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 66.1 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.8 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 415.4 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 105.2 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 341.0 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform,... which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington. Read more
Co-Founder, CEO, President, Secretary & Director
Mr. Sujal M. Patel
Co-Founder, CEO, President, Secretary & Director
Mr. Sujal M. Patel
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Nautilus Biotechnolgy Inc (NAUT) is $2.79 (NASDAQ) as of 27-Apr-2026 10:40 EDT. Nautilus Biotechnolgy Inc (NAUT) has given a return of 4.57% in the last 3 years.
Since, TTM earnings of Nautilus Biotechnolgy Inc (NAUT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.16
|
1.57
|
|
2024
|
-2.97
|
1.01
|
|
2023
|
-5.87
|
1.41
|
|
2022
|
-3.88
|
0.71
|
|
2021
|
-8.65
|
1.20
|
The 52-week high and low of Nautilus Biotechnolgy Inc (NAUT) are Rs 4.31 and Rs 0.63 as of 27-Apr-2026.
Nautilus Biotechnolgy Inc (NAUT) has a market capitalisation of $ 332 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nautilus Biotechnolgy Inc (NAUT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.